Published online Jan 24, 2022. doi: 10.5306/wjco.v13.i1.62
Peer-review started: April 2, 2021
First decision: August 18, 2021
Revised: September 22, 2021
Accepted: December 28, 2021
Article in press: December 28, 2021
Published online: January 24, 2022
Processing time: 294 Days and 7.2 Hours
Late relapses of early-stage germ cell tumors are rare. Most patients (-85%) with stage I seminoma are cured by radical orchiectomy. The detection of late relapse is challenging given the relative rarity of this phenomenon, and the fact that patients who have completed surveillance are usually not undergoing regular oncologic workup nor imaging. While many treatment options do exist for a patient with late relapse of seminoma, surgery is typically the mainstay as these tumors are generally thought to be more chemo-resistant.
In this article, we describe the management of a patient with an early-stage pure seminoma who was subsequently identified to have a recurrence two decades later. We provide a review of the literature not only focused on clinical factors and biology, but also the management of late recurrences specifically in pure semi
There is a paucity of data and treatment recommendations for this clinical entity, and a multidisciplinary approach emphasizing subspecialty expert consultation and patient education is imperative.
Core Tip: This case report describes of a patient with early-stage pure seminoma subsequently identified to have a recurrence within the prostate over two decades later. We provide a robust review of the literature focused on clinical factors, biology, and management of late recurrences specifically in pure seminoma and in prostate gland. There remains a lack of consensus data on treatment recommendations for this clinical disease. As such, a multidisciplinary approach emphasizing subspecialty expert consultation and patient education is imperative.